Article ID Journal Published Year Pages File Type
3977955 Brachytherapy 2008 4 Pages PDF
Abstract
Pretreatment PSAV is a predictor of FFBR after LDRPB in this population of men with prostate cancer. Men with a pretreatment PSAV ≥2 ng/mL/yr may warrant more aggressive treatment.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone
Authors
, , , , ,